Pregabalin sustained-release - Jiangsu HengRui Medicine

Drug Profile

Pregabalin sustained-release - Jiangsu HengRui Medicine

Alternative Names: EASOPSRTFP; Pregabalin - Jiangsu HengRui Medicine

Latest Information Update: 25 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Fibromyalgia; Postherpetic neuralgia

Most Recent Events

  • 01 May 2016 Phase-III clinical trials in Fibromyalgia in China (PO) (NCT02868814)
  • 28 Apr 2016 Jiangsu HengRui Medicine has an international patent protection for pregabalin sustained release
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top